论文部分内容阅读
目的:研究ST-段抬高心肌梗死再灌注治疗和心血管药物使用的性别差异。方法:选取2006年6月～2008年7月我院确诊为ST-段抬高心肌梗死患者病例400份分为男性和女性组,比较两组患者入院时合并疾病、心肌梗死部位、住院期间新发合并症以及再灌注治疗和心血管用药情况。结果:有男性患者292人,平均年龄64岁;女性108人,平均年龄69岁。男女患者接受冠脉血管重建术、溶栓、抗血小板和抗凝药物、β-受体阻断药、ACEI或ARB、他汀类药物、硝酸酯类、利尿药和钙通道阻断剂人数(比例)分别为:274(93.8%)与98(90.7%);12(4.1%)与6(5.6%);292(100%)与108(100%);266(91.1%)与92(85.2%);244(83.6%)与84(77.6%);256(87.7%)与87(80.6%);188(64.4%)与72(66.1%);194(66.4%)与74(68.5%)和52(17.8%)与24(22.2%),均无统计学差异。结论:急性ST-段抬高心肌梗死再灌注治疗和心血管药物利用上没有性别差异。
AIM: To investigate the gender differences in the treatment of ST-segment elevation myocardial infarction (MI) reperfusion and cardiovascular drug use. Methods: 400 cases diagnosed as ST-segment elevation myocardial infarction in our hospital from June 2006 to July 2008 were divided into male and female patients. The patients in the two groups were compared with the disease, myocardial infarction and hospitalization Incidence of complications and reperfusion therapy and cardiovascular medication. Results: There are 292 male patients, the average age of 64 years; 108 women, average age 69 years. Male and female patients underwent coronary revascularization, thrombolytic, antiplatelet and anticoagulant drugs, β-blockers, ACEI or ARB, statins, nitrates, diuretics, and calcium channel blockers ) (29.2 (100%) and 108 (100%); 266 (91.1%) and 92 (85.2%) respectively; ; 244 (83.6%) and 84 (77.6%); 256 (87.7%) and 87 (80.6%); 188 52 (17.8%) and 24 (22.2%), no statistically significant difference. CONCLUSIONS: There is no gender difference in the treatment of reperfusion of acute ST-segment elevation myocardial infarction and cardiovascular drug utilization.